Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | PGK2 | P07205 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PGD | P52209 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19281218 | 0.97 | PGK1 (0.38) | PGK1PGK2LAP3TP53PGD | |
| SCHEMBL9952548 | 0.97 | PGK1 (0.38) | PGK1PGK2LAP3TP53PGD | |
| SCHEMBL1840428 | 0.97 | PGK1 (0.38) | PGK1PGK2LAP3TP53PGD | |
| SCHEMBL27241907 | 0.95 | PGK1 (0.37) | PGK1PGK2LAP3TP53PGD | |
| SCHEMBL23931184 | 0.93 | PGK1 (0.35) | PGK1PGK2LAP3TP53PGD | |
| SCHEMBL183389 | 0.77 | SMPD1 (0.34) | PGK1PGK2SMPD1TDP1 | |
| SCHEMBL8416620 | 0.76 | PEPD (0.43) | PGK1PGK2LAP3SMPD1KDM4E | |
| SCHEMBL11522192 | 0.75 | CA4 (0.40) | LAP3PGDSMPD1TDP1 | |
| Ammonia Solution, Strong SCHEMBL28328876 | 0.75 | SMPD1 (0.33) | PGK1PGK2SMPD1TDP1 | |
| SCHEMBL12257190 | 0.75 | LAP3 (0.44) | LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390285-A1 | Lurbinectedin Composition and Methods Making the Same | PHARMA MAR SA (ES) | 2023-12-07 | — | — | US | disclosed |
| CN-105217800-A | Graphene/polypyrrole bioelectrode and preparation method and application thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2016-01-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390285-A1 | Lurbinectedin Composition and Methods Making the Same | TOP1, TOP2B, TOP2A | PGK1 2121/4885PGK2 1846/4885LAP3 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.